2012-09-17 05:58:55 - New Pharmaceuticals market report from Global Markets Direct: "Inherited Metabolic Disorders - Pipeline Review, H2 2012"

Global Markets Direct's, 'Inherited Metabolic Disorders - Pipeline Review, H2 2012', provides an overview of the Inherited Metabolic Disorders therapeutic pipeline. This report provides information on the therapeutic development for Inherited Metabolic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inherited Metabolic Disorders. 'Inherited Metabolic Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/463778_inherited_metabolic_disorders_pipelin ..


Note*: Certain sections

in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Inherited Metabolic Disorders.
* A review of the Inherited Metabolic Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Inherited Metabolic Disorders pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Inherited Metabolic Disorders.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Inherited Metabolic Disorders pipeline depth and focus of Inherited Metabolic Disorders therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Inherited Metabolic Disorders Therapeutic Products under Development, Key Players in Inherited Metabolic Disorders Therapeutics, Inherited Metabolic Disorders Pipeline Overview, Inherited Metabolic Disorders Pipeline, Inherited Metabolic Disorders Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Inherited Metabolic Disorders Overview
An Overview of Pipeline Products for Inherited Metabolic Disorders
Inherited Metabolic Disorders Therapeutics under Development by Companies
Inherited Metabolic Disorders Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Inherited Metabolic Disorders Therapeutics - Products under Development by Companies
Inherited Metabolic Disorders Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Inherited Metabolic Disorders Therapeutics Development
Genzyme Corporation
Menarini Group
ReGenX Biosciences, LLC
Nutra Pharma Corporation
Raptor Pharmaceuticals Corp.
GENETIX Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc.
Zacharon Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc.
Asklepion Pharmaceuticals, LLC.
Inherited Metabolic Disorders - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SAR402665 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RPI-78M - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Convivia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xenbilox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lenti-D - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ganglioside Inhibitor Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CYCLO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Campath-1H + Clofarabine + Melphalan + Hematopoietic Stem Cell Transplantation - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463778&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.